Azilsartan Medoxomil (Edarbi): The Eighth Angiotensin II Receptor Blocker.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. The Impact of Azilsartan Medoxomil Treatment (Capsule Formulation) at Doses Ranging From 10 to 80 mg: Significant, Rapid Reductions in Clinic Diastolic and Systolic Blood Pressure.Journal of clinical hypertension (Greenwich, Conn.) · 2017
   Trial
2. EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy--rationale and design of the EARLY hypertension registry.BMC cardiovascular disorders · 2013
   Trial
3. A Pharmacological Update of Oxadiazole Derivatives: A Review.Current topics in medicinal chemistry · 2025
   Review
4. Angiotensin Receptor Blockers and the Risk of Suspected Drug-Induced Liver Injury: A Retrospective Cohort Study Using Electronic Health Record-Based Common Data Model in South Korea.Drug safety · 2024
   Article
5. Effect of Azilsartan on clinical blood pressure reduction compared to other angiotensin receptor blockers: a systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2024
   Review
6. Role of G-protein coupled receptors in cardiovascular diseases.Frontiers in cardiovascular medicine · 2023
   Review
7. Central Composite Design Implemented Azilsartan Medoxomil Loaded Nanoemulsion to Improve Its Aqueous Solubility and Intestinal Permeability: In Vitro and Ex Vivo Evaluation.Pharmaceuticals (Basel, Switzerland) · 2022
   Article
8. Fimasartan: A new armament to fight hypertension.Journal of family medicine and primary care · 2019
   Review
9. Single-Center Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment.Journal of clinical pharmacology · 2018
   Article
10. Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry.BMC cardiovascular disorders · 2016
    Observational
11. The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.Trials · 2015
    Observational
12. Critical evaluation of the efficacy and tolerability of azilsartan.Vascular health and risk management · 2012
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.